Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

249 views

Visitors from

US 53%·

AU 33%·

IN 7%·

GB 2%·

FR 1%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

RRD Expands Diagnostic Test Kits Solution to Meet Accelerated Demand for At-Home Testing

By: RRD via Business Wire

February 09, 2023 at 09:00 AM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

With a global commitment to regulatory compliance, RRD supports a broad range of diagnostic test kit services for manufacturers, virtual care companies, retailers, and health insurance companies

R.R. Donnelley & Sons Company (RRD), a leading global provider of marketing, packaging, print, and supply chain solutions, today announced the extended portfolio of end-to-end services to support at-home testing. These services enable diagnostic device, at-home healthcare, health insurance, and point-of-care testing companies in their efforts to keep pace with the evolution of healthcare.

As the pandemic disrupted supply chains, it also shifted consumer preferences and accelerated adoption of at-home and digital healthcare. For many test manufacturers and healthcare companies, a number of challenges (e.g., labor constraints, infrastructure limitations, inventory visibility, supply irregularity, compliance, complex IT requirements, etc.) continue to stand in the way of bringing innovative new products and solutions to market.

Identifying an opportunity to provide greater support, RRD solidified its end-to-end offering that integrates and advances the regulated kitting, production, and fulfillment workstream. This solution includes a strategic alignment of the following RRD services:

Packaging and labeling solutions — structural engineering, folding cartons, rigid boxes, branded corrugated, prototyping and testing, labels, instructions for use
Sourcing and supply chain — component procurement, configuration and assembly, track and trace
Fulfillment services — direct-to-patient compliant ordering, warehousing, fulfillment
Creative and Professional Services — graphic design, kit ideation, and technology integration (Web and API)

RRD’s global network includes regulatory-compliant facilities, from FDA registration and ISO accreditation through cGMP compliance and SOC/SOC2+ for direct-to-consumer fulfillment. The company's expertise is built on nearly two decades of experience producing and kitting diagnostic and medical kits.

“There has been significant innovation and advancement in the diagnostic test kits market in recent years, and we’re now seeing increased availability of rapid testing in new categories, such as diabetes, fertility, and sexually transmitted infections,” said John Pecaric, Head of Operations at RRD. “The pandemic accelerated the emergence of diagnostic testing for point-of-care and at-home, driving the need for increased accuracy and reliability.”

Pecaric adds, “Thanks to existing global resources and decades of experience in the life sciences sector, our organization is well positioned to help clients reimagine the care experience and take their products to market without compromise. RRD has the automation capabilities, capacity, and accreditations to help clients scale operations and manage the complexity of telehealth, virtual care platforms, and health insurance requirements.”

RRD has longstanding relationships with a number of medical device providers, including Siemens Healthineers. When the FDA approved the rapid COVID-19 antigen self-test, Siemens Healthineers collaborated with RRD for the inbound receipt, inspection, warehousing, labeling, fulfillment, and logistics of the tests. RRD leveraged its supply chain expertise and ability to scale quickly to facilitate the time-sensitive project.

For more information about RRD’s vertically integrated solution for the medical diagnostics industry, visit rrd.com/diagnostic-testing.

About RRD

RRD is a leading global provider of marketing, packaging, print, and supply chain solutions that elevate engagement across the complete customer journey. The company offers the industry’s most trusted portfolio of creative execution and world-wide business process consulting, with services designed to lower environmental impact. With 25,000 clients, including 92% of the Fortune 100, and 32,000 employees across 29 countries, RRD brings the expertise, execution, and scale designed to transform customer touchpoints into meaningful moments of impact.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230209005250/en/

Contacts

Katie O’Rourke

Director, RRD Corporate Communications

media.info@rrd.com

312.326.7168

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	275.93	+3.88 (1.43%)
AAPL	280.88	+4.05 (1.46%)
AMD	350.40	+8.86 (2.59%)
BAC	53.05	+0.87 (1.66%)
GOOG	384.09	+4.45 (1.17%)
META	602.27	-8.14 (-1.33%)
MSFT	409.85	-3.77 (-0.91%)
NVDA	197.07	-1.41 (-0.71%)
ORCL	182.53	+2.25 (1.25%)
TSLA	393.66	+1.15 (0.29%)